EA201691673A1 - Замещенные циклопентаны, тетрагидрофураны и пирролидины как антагонисты орексиновых рецепторов - Google Patents
Замещенные циклопентаны, тетрагидрофураны и пирролидины как антагонисты орексиновых рецепторовInfo
- Publication number
- EA201691673A1 EA201691673A1 EA201691673A EA201691673A EA201691673A1 EA 201691673 A1 EA201691673 A1 EA 201691673A1 EA 201691673 A EA201691673 A EA 201691673A EA 201691673 A EA201691673 A EA 201691673A EA 201691673 A1 EA201691673 A1 EA 201691673A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tetrahydrofuranes
- pyrrolidines
- antagonists
- orexin receptors
- substituted cyclopentanes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Данное изобретение предлагает соединения формулы (I) и их фармацевтически приемлемые соли, где L, X, R, R, R, Rи Rимеют значения, определенные в описании, способы их получения, содержащие их фармацевтические композиции и их применение в терапии.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14156010 | 2014-02-20 | ||
PCT/GB2015/050482 WO2015124934A1 (en) | 2014-02-20 | 2015-02-19 | Subsituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201691673A1 true EA201691673A1 (ru) | 2017-01-30 |
EA031982B1 EA031982B1 (ru) | 2019-03-29 |
Family
ID=50115775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691673A EA031982B1 (ru) | 2014-02-20 | 2015-02-19 | Замещенные циклопентаны, тетрагидрофураны и пирролидины как антагонисты орексиновых рецепторов |
Country Status (20)
Country | Link |
---|---|
US (1) | US9790220B2 (ru) |
EP (1) | EP3107907A1 (ru) |
JP (1) | JP6466465B2 (ru) |
KR (1) | KR20160124188A (ru) |
CN (1) | CN106164064B (ru) |
AU (1) | AU2015220553B2 (ru) |
CA (1) | CA2940047A1 (ru) |
CL (1) | CL2016002085A1 (ru) |
CR (1) | CR20160373A (ru) |
EA (1) | EA031982B1 (ru) |
EC (1) | ECSP16074482A (ru) |
GE (1) | GEP20186909B (ru) |
IL (1) | IL247195A0 (ru) |
MA (1) | MA39229A1 (ru) |
MX (1) | MX2016010745A (ru) |
PE (1) | PE20161374A1 (ru) |
PH (1) | PH12016501625A1 (ru) |
SG (1) | SG11201606839SA (ru) |
WO (1) | WO2015124934A1 (ru) |
ZA (1) | ZA201604924B (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201613864A (en) * | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
CN106659750B (zh) | 2014-04-17 | 2021-02-12 | 韩国生命工学研究院 | 用于预防或治疗慢性阻塞性肺疾病的药物组合物 |
AU2016360245B2 (en) | 2015-11-23 | 2020-07-09 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof |
KR102298546B1 (ko) * | 2018-10-18 | 2021-09-08 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4399256B2 (ja) * | 2001-06-28 | 2010-01-13 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体アンタゴニストとしてのn−アロイル環状アミン誘導体 |
WO2008038841A1 (fr) * | 2006-09-30 | 2008-04-03 | Japan Tobacco Inc. | Dérivé de thiadiazolone et utilisation de celui-ci |
EP2491034B1 (en) * | 2009-10-23 | 2013-12-18 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds as orexin receptor modulators |
US20110144081A1 (en) * | 2009-12-15 | 2011-06-16 | Henner Knust | Pyrrolidine derivatives |
TWI570120B (zh) * | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
-
2015
- 2015-02-19 CN CN201580009703.3A patent/CN106164064B/zh not_active Expired - Fee Related
- 2015-02-19 CA CA2940047A patent/CA2940047A1/en not_active Abandoned
- 2015-02-19 EP EP15706518.6A patent/EP3107907A1/en not_active Withdrawn
- 2015-02-19 US US15/120,002 patent/US9790220B2/en not_active Expired - Fee Related
- 2015-02-19 AU AU2015220553A patent/AU2015220553B2/en not_active Expired - Fee Related
- 2015-02-19 WO PCT/GB2015/050482 patent/WO2015124934A1/en active Application Filing
- 2015-02-19 KR KR1020167025660A patent/KR20160124188A/ko unknown
- 2015-02-19 GE GEAP201514272A patent/GEP20186909B/en unknown
- 2015-02-19 EA EA201691673A patent/EA031982B1/ru not_active IP Right Cessation
- 2015-02-19 MX MX2016010745A patent/MX2016010745A/es unknown
- 2015-02-19 CR CR20160373A patent/CR20160373A/es unknown
- 2015-02-19 JP JP2016552540A patent/JP6466465B2/ja not_active Expired - Fee Related
- 2015-02-19 MA MA39229A patent/MA39229A1/fr unknown
- 2015-02-19 PE PE2016001444A patent/PE20161374A1/es unknown
- 2015-02-19 SG SG11201606839SA patent/SG11201606839SA/en unknown
-
2016
- 2016-07-15 ZA ZA2016/04924A patent/ZA201604924B/en unknown
- 2016-08-09 IL IL247195A patent/IL247195A0/en unknown
- 2016-08-15 PH PH12016501625A patent/PH12016501625A1/en unknown
- 2016-08-18 CL CL2016002085A patent/CL2016002085A1/es unknown
- 2016-09-15 EC ECIEPI201674482A patent/ECSP16074482A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201606839SA (en) | 2016-09-29 |
CN106164064B (zh) | 2019-03-22 |
WO2015124934A8 (en) | 2016-07-21 |
PE20161374A1 (es) | 2016-12-17 |
EP3107907A1 (en) | 2016-12-28 |
ZA201604924B (en) | 2019-04-24 |
WO2015124934A1 (en) | 2015-08-27 |
JP6466465B2 (ja) | 2019-02-06 |
ECSP16074482A (es) | 2018-05-31 |
US9790220B2 (en) | 2017-10-17 |
IL247195A0 (en) | 2016-09-29 |
CL2016002085A1 (es) | 2017-06-09 |
CA2940047A1 (en) | 2015-08-27 |
AU2015220553A1 (en) | 2016-07-21 |
PH12016501625A1 (en) | 2016-11-07 |
MX2016010745A (es) | 2017-02-02 |
CN106164064A (zh) | 2016-11-23 |
EA031982B1 (ru) | 2019-03-29 |
JP2017506239A (ja) | 2017-03-02 |
US20170073340A1 (en) | 2017-03-16 |
AU2015220553B2 (en) | 2019-06-27 |
CR20160373A (es) | 2016-12-02 |
MA39229A1 (fr) | 2018-01-31 |
GEP20186909B (en) | 2018-10-25 |
KR20160124188A (ko) | 2016-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
EA202090486A3 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201691674A1 (ru) | 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина | |
EA201691302A1 (ru) | Новые гетероциклические соединения | |
EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
EA201691853A1 (ru) | Агонисты мускариновых рецепторов | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
EA201790570A1 (ru) | Модуляторы р2х7 | |
CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
EA201691673A1 (ru) | Замещенные циклопентаны, тетрагидрофураны и пирролидины как антагонисты орексиновых рецепторов | |
EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
EA201691493A1 (ru) | Замещенные n-арилпиридиноны |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |